Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Join SI Premium – FREE
Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75).
For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q2 EPS by 15c; raises guidance
- Galderma Agrees To Buy Zo Skin Health from Blackstone For Around $1.5 Billion - Reuters
- Gates launches polyurethane conveyor belt for warehouse automation
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
